Our findings differ from those reported by Shieu et al. [22] in oral squamous cell carcinoma, where Narciclasine promoted expression of the epithelial marker ZO-1 and reduced expression of mesenchymal markers (CDH2, and β-catenin). The gene discussed is CDH2; the disease is oral cavity squamous cell carcinoma.